21 November 2024 –
Neomatrix, a pioneering biotech firm, has successfully closed EUR 1.5 million in additional funding led by existing investors 2Invest AG and i2i Capital Limited. This new investment will be crucial in completing the regulatory development for its proprietary personalized cancer vaccines and exploring innovative combination strategies.
“We are excited to receive this funding, which will propel Neomatrix Cancer Vaccines towards clinical proof-of-concept next year,” said Luigi Aurisicchio, Ph.D., Chief Executive Officer and President of Neomatrix. “Our team has achieved significant scientific objectives and regulatory milestones, positioning us to further advance our groundbreaking technology platform.”
Neomatrix's personalized cancer vaccines utilize a cutting-edge process that begins with a tumor biopsy. This process identifies “neoantigens,” which are cancer-specific mutations recognizable by the immune system. An individualized vaccine is then created using fully synthetic DNA, delivered through electroporation, a clinically validated and highly effective delivery method. The synthetic DNA platform has been developed in collaboration with 4BaseBio, a strategic partner of Neomatrix.
“In just one year, we have established robust preclinical data, refined our DNA production process, and received strategic guidance from regulatory agencies,” stated Fabio Palombo, founder and Chief Scientific Officer of Neomatrix. “While our technology will initially target lung cancer, it is versatile enough for precision vaccine strategies across a variety of tumor types. This funding also enables us to investigate new combination modalities in oncology.”
Heikki Lanckriet, CEO and CSO of 4BaseBio, added: “Our close collaboration with Neomatrix will facilitate the manufacture of personalized vaccines and expand our technology for new applications.”
Hansjörg Plaggemars, representing 2Invest and i2i, expressed his enthusiasm: “We are impressed by the Neomatrix team's rapid development of the skills and expertise necessary to advance cancer vaccines to the next stage.”
Aurisicchio concluded: “We are grateful for the continued interest from 2Invest AG and i2i Capital Limited, recognizing Neomatrix as a strategic fit within their investment portfolios. Our promising technology positions Neomatrix to explore new frontiers and establish further strategic partnerships.”
For more info:
Dr Luigi Aurisicchio (CEO)
Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
Dr Fabio Palombo (CSO)
Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
Neomatrix
Neomatrix is a biotech company created by a group of scientists with solid experience in Pharma and Biotech. The group has more than 15 years of experience and proven expertise in drug discovery in Oncology and is recognized for the design and implementation of a number of innovative technologies, including that of DNA gene therapy. Neomatrix’ core assets is its experience in the prediction of neoantigens and with electroporation delivery system, a technology that can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy.
For more info, visit www.neomatrixbiotech.com
2Invest AG
2invest AG is a listed company that acquires, holds, manages and sells shares in companies and partnerships, mainly - but not exclusively - in the biotechnology, life sciences and IT sectors as well as in the natural resources in Germany and abroad. Global investments or investments in unlisted companies or financial instruments are also possible. Investment decisions are made on the basis of interesting risk/return profiles. The company is listed on the General Standard of the Frankfurt Stock Exchange (Ticker: 2INV; ISIN: DE000A3H3L44).
I2i Capital Limited
I2i Capital Limited is a UK company focussed on investments in the field of life sciences.
